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A subunit approach to the development of a respiratory syncytial virus (RSV) vaccine was investigated. It involved
the production, in Escherichia coli, of an RSV (Long) G protein fragment (G2Na) as a C-terminal fusion partner to an
albumin binding region (BB) of streptococcal protein G. G2Na incorporated amino acid residues 130 – 230 and was
specifically recognized by murine anti-RSV-A polyclonal serum. In mice, intraperitoneal immunization with BBG2Na
induced high anti-RSV-A serum ELISA titers and low to moderate neutralization activity. The immune response induced
by BBG2Na demonstrated a potent protective efficacy against upper and lower respiratory tract RSV-A infection. The
immunogenicity and protective efficacy of BBG2Na was maintained for at least 47 and 48 weeks, respectively, and was
as potent and durable as live RSV-A administered in a similar fashion. Intramuscular immunization of cotton rats with
BBG2Na protected lungs from both homologous and heterologous virus challenge. In contrast to mice, however, cotton
rat nasal tracts were not protected after BBG2Na immunization. Consistent with antibody-mediated protection, virus
was cleared within 24 hr from the lungs of BBG2Na-immunized mice. The anti-RSV-A antibodies induced in mice were
exclusively of the IgG1 isotype and were detected in the serum, lungs, and nasal tracts. Passive transfer of these
antibodies prevented acute, and eliminated chronic, RSV-A lung infection in normal and immunodeficient mice, respec-
tively, confirming that such antibodies are important and sufficient for BBG2Na-induced pulmonary protection. Our
results clearly demonstrate that BBG2Na contains an important immunogenic domain of the RSV G protein. The prokary-
otic origin of this protein indicates that glycosylation of the RSV G protein is not necessary for protective efficacy.
Thus, BBG2Na has potential as an RSV subunit vaccine. q 1997 Academic Press
INTRODUCTION infants to heavily glycosylated proteins in general (Cha-
nock et al., 1992), and RSV G protein in particular (Wagner
Respiratory syncytial virus (RSV) is one of the most et al., 1989), provided the rationale for prokaryotic expres-
common causes of serious respiratory infection in infants sion. Resultant recombinant proteins are intrinsically
(Collins et al., 1996). Despite its clinical importance, there nonglycosylated. The fragment incorporated the G pro-
is no RSV vaccine available. In the 1960s a formalin- tein sequence between residues 130 and 230 inclusive
inactivated alum-precipitated whole RSV preparation (FI- (designated G2Na).
RSV) not only failed to protect, it was also associated Although RSV G proteins are highly variable and pri-
with disease enhancement upon subsequent infection marily responsible for the division of human and bovine
with wild-type virus (Kim et al., 1968). Since then many RSV isolates into subgroups (A or B) (Cane and Pringle,
strategies have been explored in the search for an effec- 1995; Furze et al., 1994; Garcia et al., 1994; Mufson et
tive and safe vaccine, primarily employing live attenuated al., 1985; Sullender et al., 1991), this G protein fragment
virus or eukaryote-derived native or recombinant viral
was targeted because: (1) the G protein is one of the
subunits (for review see Murphy et al., 1994). In an alter-
principle RSV immunogens in humans and rodents (Col-
native approach, we expressed a RSV-A (Long strain) G
lins et al., 1996); (2) a recombinant vaccinia virus (rVV)
protein fragment as part of a fusion protein in Escherichia
expressing a C-terminus deleted G protein (G230) pro-coli (Murby et al., 1995). The highly glycosylated nature
tected cotton rats from homologous virus challenge asof the RSV G protein (Collins et al., 1996), the potential for
efficiently as full-length protein (Olmsted et al., 1989); (3)oligosaccharides to mask or diminish relevant immune
the N-terminus of the fragment coincided with the C-responses (Alexander and Elder, 1984; Elder et al., 1986;
terminus of a subgroup A G protein hypervariable regionSkehel et al., 1984), and the poor response of young
(Cane et al., 1991; Cane and Pringle, 1995; Garcia et al.,
1994); (4) it contains a conserved subgroup A-specific
protective epitope (A˚kerlind-Stopner et al., 1990; Trudel1 To whom correspondence and reprint requests may be addressed.
Fax: 33.4.50.35.35.90. et al., 1991); (5) residues 163–190 and 160–189 of sub-
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groups A and B, respectively (within which the subgroup- mined by the Lowry method (Lowry et al., 1951). The
proteins were analyzed for purity and antigenicity byspecific epitope is located), are completely conserved
among known G protein sequences of their respective SDS–PAGE on 9% homogenous gels under reducing
conditions and Western blots using RSV-A-specific se-subgroups (Cane et al., 1991; Garcia et al., 1994; Sul-
lender et al., 1991); (7) residues 164–176 are completely rum, respectively.
conserved in all known human RSV isolates (Collins et
Viruses and cellsal., 1996); and (8) evidence for a role of G in FI-RSV-
induced enhanced pathology is contradictory (Murphy et Respiratory syncytial virus subgroup A (RSV-A) (Long
al., 1989; Piedra et al., 1993; Vaux-Peretz et al., 1992), strain) (ATCC VR-26, American Type Culture Collection,
although the potential for such a role exists (Alwan et Rockville, MD) and RSV-B (strain 8/60) (kindly provided
al., 1994; Hancock et al., 1996). by Dr. G. Taylor, Institute of Animal Health, Compton,
The RSV G fragment was fused to the C-terminus of UK) were propagated in HEp-2 cells (ECACC 86030501,
an albumin binding region (BB) of streptococcal protein European Collection of Animal Cell Cultures, Porton
G (Nygren et al., 1988). BB was chosen as a fusion part- Down, Salisbury, UK) as previously described (Trudel et
ner for several reasons. It was demonstrated that BB al., 1991), except that medium was supplemented with
fusions significantly increased the in vivo half-lives in 1% fetal calf serum. Viruses were harvested after 48–72
rodent and nonhuman primate models of proteins in- hr by scraping attached cells into the medium, centrifug-
tended for therapeutic use (Makrides et al., 1996; Nygren ing the suspension at 460 g for 15 min, and collecting
et al., 1991), thereby resulting in prolonged exposure of the supernatant as the virus stock. The pellet was used
the immunogen to the immune system. Furthermore, BB to prepare viral protein ELISA antigen as previously de-
exhibited carrier-related properties since antibody re- scribed (Furze et al., 1994). Uninfected HEp-2 cells were
sponses to fused peptides were significantly enhanced prepared in a similar manner as cell control ELISA anti-
(Sjo¨lander et al., 1997). Finally, because of its high affinity gens.
for human, mouse, and rat serum albumin, BB fusion
proteins can be efficiently purified by affinity chromatog- Animals
raphy on albumin–Sepharose (Nygren et al., 1988).
Female BALB/c mice and cotton rats (Sigmodon his-While prokaryotically expressed RSV proteins demon-
pidus), aged 6–9 weeks, were purchased from IFFAstrated antigenicity (Murby et al., 1995; Mazumder et al.,
CREDO, L’Arbresle, France, for use in protection studies.1994; Nguyen et al., 1995) and immunogenicity (Louns-
These animals were confirmed seronegative vis-a`-visbach et al., 1993; Martin-Gallardo et al., 1991, 1993), their
RSV before inclusion in the studies. Protective efficacy ofprotective efficacy has not been documented. Indeed,
passively transferred polyclonal sera was studied usingprecedents for protective efficacy of prokaryotically ex-
naive BALB/c and C.B-17 scid/scid mice (IFFA CREDO).pressed recombinant proteins of any virus are exceed-
All animals were fed rat and mouse maintenance dietingly rare (Manning and Leong, 1990; Srivastava et al.,
A04 (UAR, Villemoissin-sur-Orge, France) and water ad1991, 1995). In this communication we addressed the
libitum, and they were housed and manipulated ac-purification, antigenicity, immunogenicity, and protective
cording to national and European guidelines. Mice wereefficacy of prokaryotically expressed BBG2Na against
immunized intraperitoneally (ip) with a total 200-ml vol-homologous and heterologous virus challenge. The role
ume or intramuscularly (im) with a total 100-ml volume, inof humoral immunity in BBG2Na-induced protection was
PBS containing 20% Alhydrogel (Al(OH)3) (v/v) (Superfosalso studied. The implications of the results regarding
BioSector a/s, Vedbaek, Denmark). Cotton rats were im-immunogenicity of the RSV G protein fragment, and the
munized im with 200 ml in PBS containing 20% Alhydrogelrole of glycosylation in protective immunity, are dis-
(v/v). An interval of 2 weeks was invariably employed forcussed.
second and subsequent immunizations. Except where
indicated, animals were bled 2 weeks after the last immu-MATERIALS AND METHODS
nization, challenged 3 weeks postimmunization with 105
Gene assembly, vector constructions, and expression tissue culture infectious doses50 (TCID50) RSV-A or -B by
intranasal (i.n.) instillation, and sacrificed 5 days post-Gene assembly, vector constructions, expression, and
challenge, coincident with previously characterized peakfirst-step protein purification of BBG2Na and BB were
RSV lung titers (Taylor et al., 1984b).undertaken as previously described (Murby et al., 1995;
Nguyen et al., 1994; Sta˚hl et al., 1989). Lyophilized pro-
ELISA assays
teins were solubilized in a solution containing 90% 40
mM triethylammonium formiate buffer, pH 3.0 (TEAF: Anti-immunogen and anti-virus antibody titers in se-
rum, bronchoalveolar lavage (BAL), or nasal tract lavageHPLC solvent A), and 10% of TEAF, 90% CH3CN (HPLC
solvent B) and further purified by reverse-phase HPLC. (NTL) samples were assessed by ELISA. Briefly, microti-
ter plates were coated overnight at 47 with 50 ml per wellProtein content of pooled purified fractions was deter-
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of a 4 mg/ml solution of BBG2Na in PBS or at 377 and ml gentamicin, 0.22 M sucrose, 30 mM MgCl2 , 0.5 mg/
ml fungizone). Ten percent suspensions of lung tissueslow humidity with 50 ml of RSV-A, RSV-B, or HEp-2 cell
protein preparations. The plates were blocked at 377 with (w/v) in virus transport medium were prepared in dounce
homogenizers and centrifuged at 460 g for 15 min. NTLs200 ml/well of PBS containing 4% milk solids (w/v) for at
least 2 hr and incubated for 2 hr at room temperature were undertaken by forcibly injecting 1.5 ml of virus
transport medium into the nasopharyngeal cavity of de-(RT) with 50 ml/well of PBS containing 0.4 or 4% milk
solids (for mice and cotton rats, respectively) and three- capitated animals and recovering exudate from the na-
res. The exudate was centrifuged at 2800 g for 5 min.fold serial dilutions of the samples. Negative controls
consisted of wells to which no samples were added. Lung homogenate and NTL supernatants were snap-
frozen and stored in liquid nitrogen until assayed forPlates were washed with PBS 0.05% Tween 20 (Sigma)
and incubated 1 hr at RT with 50 ml/well horseradish virus. Virus titers in these samples were determined by
titration assays as previously described (Dougherty,peroxidase (HRP)-conjugated anti-mouse IgG heavy and
light chains (1/5000) (Interchim, Monluc¸on, France) or 1964). Cytopathic effects were monitored on Days 5 and
7 and virus titers calculated according to Ka¨rber’santi-rat IgG antibody (1/5000) (ICN Biomedicals, Orsay,
France). For IgA and IgG subclass studies, HRP-conju- method (Dougherty, 1964). The limit of detection for lung
tissues was log10 £ 1.45/g, except where insufficientgated anti-mouse IgA (1/4000) (Southern Biotechnology
Associates, Inc.; Birmingham, AL), IgG1 and IgG2a (1/ lung homogenate was available. The limit of detection
for NTL samples was invariably log10 £ 0.45/ml. Actual8000) (Interchim), and IgG2b (1/1600) and IgG3 (1/1600)
(ICN Biomedicals) antibodies were used as secondary detection limits were employed for statistical analyses,
and thus standard deviations above 0 were occasionallyantibodies. After being washed 50 ml tetramethyl benzi-
dine (Kirkegaard and Perry Laboratories Inc., Gaithers- recorded for lung titers of some animal groups in which
no virus was detected. Animal organs were consideredburg, MD) was added per well for 5 min at RT. The reac-
tion was terminated with 50 ml/well 1 M HCl. Optical protected when virus titers were reduced by at least 2
log10 relative to PBS-immunized control mice.densities (OD) were measured at 450 nm. ELISA titers
were expressed as the reciprocal of the last dilution with
an OD ⁄ 0.15 and at least twofold that of the negative Statistical analyses
control. As the virus stocks contained cellular antigen,
Statistical analyses were undertaken using the soft-anti-RSV-A-specific titers, or B-specific antibody titers in
ware SAS (Statistical Analysis System, SAS Institute, NC,RSV-A-immunized animals were calculated by sub-
Release 6.07).tracting anti-HEp-2 titers from those of anti-RSV-A.
RESULTSVirus neutralization assays
Major problems related to the use of prokaryotic ex-Neutralization assays were undertaken in triplicate.
pression systems for the production of recombinantMixtures of 50 ml each of an RSV-A suspension (103
mammalian viral proteins include low expression levels,TCID50/ml) and twofold serial dilutions of antiserum
lack of posttranslational processing, proteolytic instabil-were incubated for 4 hr at 47. Fifty microliters of each
ity, and complicated purification and renaturation proce-mixture was then added per well to HEp-2 monolayers
dures. BBG2Na, however, was expressed in E. coli atin 96-well plates and incubated at 377 for 2 hr, before
high levels with approximately 0.7–0.8 g fusion protein/being overlaid with 200 ml of 1% (w/v) methyl cellulose
liter bacterial culture. The two-step purification resultedsemisolid culture medium. After 2 – 3 days at 377 in a
in a highly pure gene product (95% homogeneous) thathumidified atmosphere containing 5% CO2 , the plates
migrated in accordance with its theoretical molecularwere emptied, and the cells were fixed with 10% forma-
weight (38.6 kDa) and was specifically recognized bylin, washed with PBS and stained with 0.1% crystal
a murine anti-RSV-A polyclonal serum, as determined byviolet (w/v) in PBS containing 2% citric acid (w/v). Neu-
Western blot (data not shown).tralization titers were expressed as the reciprocal of
the highest dilution that reduced positive control syn-
Immunogenicity of BBG2Na in BALB/c mice vis-a`-viscytium numbers by at least 60%.
RSV-A
Animal sample preparation and virus titration
To determine the immunogenicity of BBG2Na, groups
of 6 – 12 mice were immunized three times ip with 2- orAnimals were anesthetized with 2.5 ml/kg of a 4/1
mixture (v/v) of ketamine (Imalge`ne 500) (Rhoˆne Me´rieux, 20-mg doses of BBG2Na. Control groups received either
PBS alone or approximately 105 TCID50 RSV-A ip. Two,Lyon, France) and xylazine (Rompun at 2%) (Bayer, Pu-
teaux, France) and exsanguinated by cardiac puncture. 11, 23, 35, and 47 weeks after the last immunization
anti-BBG2Na and anti-RSV-A serum ELISA titers wereLungs were removed and placed in 1 ml of virus trans-
port medium (Hanks 199 (11), 25 mM HEPES, 0.05 mg/ determined. Serum dilutions resulting in 60% anti-RSV-
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FIG. 1. Humoral immune responses in BBG2Na-immunized mice. Mice were immunized three times ip at 2-week intervals with BBG2Na (2 or 20
mg), RSV-A (Long) (105 TCID50 in PBS) or PBS alone. Twenty percent Alhydrogel (v/v) was used as adjuvant for all immunizations. (A) Geometric
means of serum antibody ELISA titers at 2, 11, 23, 35, and 47 weeks after the final immunization; recognizing BBG2Na (—1—, mice immunized
with 20 mg BBG2Na; — —, mice immunized with 2 mg BBG2Na); recognizing RSV-A (— —, mice immunized with 20 mg BBG2Na; —L—, mice
immunized with 2 mg BBG2Na; , RSV-A-immunized mice; —l—, PBS-immunized mice). Eleven to 48 sera were included in the test groups,
while 5–23 were in the control groups. The limit of detection of the assay (log10 1.95) is indicated by an arrow and a broken line. (B) Geometric
means of serum neutralizing activity titers obtained in a microneutralization assay against RSV-A in mice immunized with 20 mg BBG2Na (— —),
2 mg BBG2Na (—L—), RSV-A ( ), or PBS (—l—). (C) Localization of anti-RSV-A antibodies in BBG2Na-immunized mice. Sera, nasal tract, and
bronchoalveolar lavages were tested in ELISA for total anti-RSV-A IgG antibodies 3 weeks after the final immunization. (D) Isotype of anti-RSV-A
antibodies in BBG2Na-immunized mice—results are presented only for serum samples obtained 3 weeks after the last immunization.
A serum neutralization activity were also determined. approximately 1 log10 higher. These titers diminished at
a slow but progressive rate thereafter. However, evenBBG2Na was highly immunogenic vis-a`-vis itself and
RSV-A, as demonstrated in Fig. 1A. Indeed, at 2 weeks at 47 weeks postimmunization with BBG2Na, anti-RSV-
A antibody titers remained substantial, indicating that apostimmunization, BBG2Na-induced anti-RSV-A anti-
body titers were similar to those elicited by RSV-A (ap- solid, long-term B cell memory response was induced.
In comparison with BBG2Na, anti-RSV-A antibody titersproximately log10 5.5), while anti-BBG2Na titers were
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in RSV-A immunized mice did not depreciate over the
duration of the experiment. Under these experimental
conditions, no BBG2Na dose effect was evident on se-
rum antibody titers. All BBG2Na-immunized mice dem-
onstrated detectable RSV-A serum neutralizing activity
(Fig. 1B). In general, average neutralizing titers ranged
from low to moderate and were independent of the
doses administered. Highest average titers (log10 1.96)
were evident at 2 weeks postimmunization, but they
remained relatively stable for the duration of the experi-
ment. Neutralization titers were similar to those induced
by RSV-A for at least 23 weeks postimmunization. How-
ever, at 35 weeks RSV-A-induced neutralization activity
rose significantly and continued to do so until the end
of the experiment, such that the average neutralizing
titer at 47 weeks was log10 2.96.
To determine the localization and isotype of anti-RSV-
A antibodies in BBG2Na-immunized mice, 27 mice were
immunized 3 times ip with 20 mg BBG2Na and sacrificed
3 weeks later. Individual sera were obtained by cardiac
puncture, NTLs were undertaken as described above,
and BALs were undertaken by repeatedly injecting 0.7
ml PBS into the lungs via the trachea and aspirating into
the syringe. Total IgG and IgA anti-RSV-A ELISA titers
were determined for individual samples from each of
the 27 mice. As anticipated by the parenteral route of
immunization, anti-RSV-A-specific IgA antibodies were
never detected in the nasal tract, BAL, or serum of
BBG2Na-immunized mice. In contrast, anti-RSV-A total
IgG serum titers were very high (Fig. 1C), while elevated
and low titers were evident in BAL and NTL, respectively.
These results indicated that BBG2Na-induced anti-RSV- FIG. 2. Duration of lung and nasal tract protection. Mice were immu-
nized three times ip at 2-week intervals with BBG2Na (2 or 20 mg) (nA IgG antibodies were present in the sites of RSV-A
 11–12/group), RSV-A (Long) (105 TCID50 in PBS) or PBS alone (n respiratory tract infection. These antibodies were exclu-
5–6/group, except at 3 weeks where n 3). Twenty percent Alhydrogelsively of the IgG1 isotype, whether in the serum (Fig. 1D),
(v/v) was used as adjuvant for all immunisations. Mice were challenged
BAL, or nasal tract (data not shown). 3, 12, 24, 36, or 48 weeks after the last immunization and sacrificed 5
days later. Results represent geometric means of individual mice in
each group. Detection limits are indicated by arrows and broken lines.Protective efficacy of BBG2Na in BALB/c mice
(A) Duration of lung protection against RSV-A challenge. Ten percentagainst homologous virus challenge lung homogenates were prepared and virus titers determined as de-
scribed under Materials and Methods. (B) Duration of nasal tract pro-
The protective efficacy of BBG2Na was determined tection against RSV-A challenge. Nasal passages were rinsed by forc-
using the mice implicated in the long-term immunogenic- ibly injecting 1.5 ml virus transport medium into the nasopharyngeal
cavity and recovering the exudate from the nares. Nasal lavage virusity studies described above. They were challenged at 3,
titers were determined as described under Materials and Methods.12, 24, 36, and 48 weeks postimmunization. Consistent
(— —) mice immunized with 20 mg BBG2Na; (—L—) mice immunizedwith anti-RSV-A antibody detection, BBG2Na completely
with 2 mg BBG2Na; ( ) RSV-A-immunized mice; (—l—) PBS-im-
prevented detectable RSV-A infection in the lungs of mice munized mice.
challenged 3 weeks after the last immunization (Fig. 2A).
This sterilizing protection persisted in 82–100% of ani-
mals for the entire 48 weeks of the experiment. These were reduced by at least log10 1.74 compared with PBS-
immunized controls. Indeed, at 48 weeks postimmuniza-results compared favorably with those of RSV-A-immu-
nized mice, thereby indicating that BBG2Na-induced pul- tion with 20 and 2 mg BBG2Na, upper respiratory tracts
were protected in 55 and 83% of the animals, respec-monary protection is as potent and durable as that of
live RSV-A administered in a similar fashion. tively, while 33 and 75%, respectively, had no, or mini-
mally, detectable virus. To our knowledge, such data areIn addition to lung protection, BBG2Na demonstrated
a nasal tract protective efficacy which also compared unprecedented for RSV subunit or live attenuated vac-
cines. Interestingly, nasal tract protective efficacy wasfavorably with RSV-A (Fig. 2B). Mean NTL virus titers
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less efficient after im administration of BBG2Na (data not
shown). Nonetheless, the mean virus NTL titer in animals
that received two doses of 2 mg BBG2Na im was signifi-
cantly reduced relative to PBS-immunized controls. Also,
im administration of BBG2Na was more efficient at induc-
ing nasal tract protective immune responses than RSV-
A administered in a similar fashion.
Homologous and heterologous immunogenicity and
protective efficacy of BBG2Na in cotton rats
Fifty-three percent homology between the relevant RSV
subgroup A and B G protein fragments, and the mapping
of a cross-reactive epitope within this region (Rueda et
al., 1994), suggested that BBG2Na may be immunogenic
and protective vis-a`-vis RSV-B. To address this question,
and to confirm BBG2Na-induced homologous protection
in a second animal model, groups of 5–14 cotton rats
were immunized im three times with 20 mg BBG2Na.
Control groups received 200 ml PBS. Animals were bled
2 weeks after the last immunization to determine anti-
BBG2Na, anti-RSV-A, or RSV-B serum antibody titers. Cot-
ton rats demonstrated moderately high serum antibody
titers to BBG2Na and RSV-A (Fig. 3A). In contrast, anti-
RSV-B serum ELISA titers were either very low or unde-
tectable.
Three weeks postimmunization cotton rats were chal-
lenged with RSV-A or RSV-B and sacrificed 5 days later
to quantify lung and nasal tract virus titers. Consistent
with the mouse model, no virus was detected in the lungs
of BBG2Na-immunized cotton rats after homologous vi-
rus challenge (Fig. 3B). Significantly, BBG2Na also in-
duced extensive cross-protection of cotton rat lungs. Av-
erage RSV-B lung titers were reduced by log10 2.25 com-
pared with PBS-immunized controls; the majority of
cotton rats had no, or minimally, detectable virus. These
results were consistent with, and confirmed by, cross-
protection in the lungs of BALB/c mice, where two immu-
nizations ip of 20 mg BBG2Na protected against RSV-
B challenge (data not shown). However, in contrast to
homologous nasal tract protection in the mouse model,
BBG2Na immunization failed to protect cotton rat nasal
tracts against RSV-A or B challenge (Fig. 3C). Compari-
son with heterologous protection in mice was not feasi-
ble as RSV-B strain 8/60 NTL titers were very low, even
after i.n. challenge with 106 TCID50 RSV-B.
in cotton rats. Sera were tested in ELISA against BBG2Na, RSV-A, and
RSV-B (sera from PBS-immunized controls were invariably negative in
ELISA against all 3 antigens). (B) Lung protection against homologous
and heterologous virus challenge. Ten percent lung homogenates were
FIG. 3. Humoral and protective immune responses in cotton rats. prepared and virus titres determined as described under Materials and
Cotton rats were immunized 3 times im at 2-week intervals with 20 mg Methods. (C) Nasal tract protection against homologous and heterolo-
BBG2Na or PBS (n  5–14/group). Twenty percent Alhydrogel (v/v) gous virus challenge. Nasal passages were rinsed by forcibly injecting
was used as adjuvant for all immunizations. Cotton rats were bled from 1.5 ml virus transport medium into the nasopharyngeal cavity and recov-
the retro-orbital venous plexus 2 weeks after the last immunization, ering the exudate from the nares. Nasal lavage virus titers were deter-
challenged 1 week later, and sacrificed 5 days postchallenge with mined as described under Materials and Methods. (j) BBG2Na-immu-
either RSV-A (Long) or RSV-B (8/60). (A) Humoral immune responses nized animals; (…) PBS-immunized mice.
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FIG. 4. Kinetics of virus disappearance from the lungs (A) and nasal tract (B) of mice immunized with BBG2Na. Mice were immunized 2 times ip
at 2-week intervals with 20 mg BBG2Na, RSV-A, or PBS (n  50) and challenged 3 weeks later with RSV-A. Twenty percent Alhydrogel (v/v) was
used as adjuvant for all immunizations. All mice were challenged with RSV-A 3 weeks after the last immunization. Groups of 10 mice were sacrificed
at 30 min and at 1, 2, 3, and 4 days postchallenge. Lung and nasal tract virus titrations were as described under Materials and Methods. (— —)
BBG2Na-immunized mice; (— —) RSV-A-immunized mice; (—L—) PBS-immunized mice.
Kinetics of virus clearance from BALB/c mouse nasal tracts of RSV-A-immunized mice was slightly
slower and less efficient than from BBG2Na-immunizedtissues
mice. Indeed, virus was detectable in the nasal tracts of
The absence of RSV-A in BBG2Na-immunized mice 5
all animals tested, although 70% were considered pro-
days postchallenge prompted us to address the kinetics
tected by Day 4.
of virus clearance from the respiratory tract. To do so,
50 mice were immunized two times ip with 20 mg Prophylactic and therapeutic efficacy of passively
BBG2Na (with PBS and RSV-A as controls) and chal- transferred anti-BBG2Na polyclonal serum
lenged with RSV-A 3 weeks later. Groups of 10 mice
were sacrificed 30 min, 1 day, 2 days, 3 days, and 4 days The rapid kinetics of virus clearance from mouse respi-
ratory tracts suggested that antibodies were importantpostchallenge and lung and nasal tract virus titers were
determined. BBG2Na- and RSV-A-immunized mice dem- mediators of BBG2Na-induced protection. To determine
such a role, sera from 50 mice immunized with BBG2Na,onstrated similarly high anti-RSV-A serum antibody titers
at 2 weeks postimmunization, while PBS-immunized as described above for antibody localization, were
pooled and employed in passive transfer experiments.mice remained seronegative (data not shown). High RSV-
A titers were recovered in the lungs and NTLs of all Tenfold dilutions in 50-ml volumes, starting with an equiv-
alent ELISA titer of 104 vis-a`-vis RSV-A, were instilled i.n.animals 30 min postchallenge (Figs. 4A and B). Thereaf-
ter, viable virus was rapidly cleared from the lungs of to groups of 7 anesthetized naive mice 1 day before RSV-
A challenge. Controls received serum from mice immu-BBG2Na-immunized mice, with 80% virus-free within 24
hr. By 2 days, virus was no longer detectable in the lungs nized with an irrelevant protein designated P40. Mice
were sacrificed 5 days postchallenge. As shown in Fig.of these animals. RSV-A-immunized mice demonstrated
parallel virus clearance kinetics, although virus was de- 5A, anti-BBG2Na polyclonal serum protected mouse
lungs against RSV-A challenge in a dose-dependenttectable in the lungs of more animals, and for a longer
period (up to Day 4). The kinetics of virus clearance from manner. All mice that received the highest antibody dose
were protected with no, or minimally, detectable virus inthe nasal tract of BBG2Na-immunized mice were less
spectacular than lung clearance kinetics. Nonetheless, their lungs. Interestingly, while not protective, even the
lowest dose tested resulted in a significant average lungan average NTL virus titer reduction of almost log10 1.5
was evident by Day 1 postchallenge compared with PBS- virus titer reduction (P  0.001). Similar lung protection
was observed after passive transfer of anti-BBG2Na ip,immunized controls (Fig. 4B), while 2/10 NTLs were virus
free. By Day 4, the nasal tracts of 80% of these animals although higher doses were required for equivalent effi-
cacy (data not shown). In contrast to lung protection,were considered protected. Elimination of virus from the
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FIG. 5. Prophylactic and therapeutic efficacy of passively transferred anti-BBG2Na polyclonal serum. A pool of serum from 50 mice immunized
3 times with 20 mg BBG2Na ip at 2-week intervals and sacrificed 3 weeks postimmunization was used in the passive transfer studies. Control sera
were provided by immunizing groups of 25 mice with either an irrelevent protein (P40) or recombinant BB alone, as described above for BBG2Na.
Twenty percent Alhydrogel (v/v) was used as adjuvant for all immunizations. (A) Prophylactic efficacy of anti-BBG2Na. Serial dilutions of anti-BBG2Na,
starting with an anti-RSV-A ELISA titer equivalent of 104, were passively transferred to groups of naive BALB/c mice (n  7) by i.n. instillation in a
50-ml volume. Control mice received an anti-P40 ELISA titer equivalent of 104. Mice were challenged with RSV-A 24 hr later and sacrificed 5 days
postchallenge. Lung virus titers were determined as described under Materials and Methods. (B) Therapeutic efficacy of anti-BBG2Na. Twenty-six
days postinfection with RSV-A, groups of 7 SCID mice received either anti-BBG2Na (at an anti-RSV-A ELISA titer equivalent of 104) or anti-BB (at
an anti-BB titer equivalent of 104) by i.n. instillation in a 50-ml volume. Mice were sacrificed 5 days later and lung virus titers were determined as
described under Materials and Methods.
neither i.n. nor ip passive transfer of anti-BBG2Na poly- results also confirm that anti-BBG2Na-mediated protec-
tion is specific to anti-G2Na antibodies.clonal serum protected the nasal tracts of mice from
homologous virus challenge (data not shown).
Immunocompromised mice were previously shown to DISCUSSION
be susceptible to chronic infection by RSV (Taylor et al.,
1985). Thus, we developed a C.B-17 scid/scid (SCID) The strategy we employed to study the vaccine poten-
tial of an RSV-A G protein fragment was to express it asmouse RSV infection model to determine the capacity of
anti-BBG2Na polyclonal serum to eliminate virus from part of a fusion protein with BB in E. coli. The prokaryotic
production was of particular interest because of the highthe lungs of chronically infected mice. Groups of seven
mice were infected i.n. with 105 TCID50 RSV-A. Twenty- oligosaccharide content of the native RSV G protein (Col-
lins, 1991), which is potentially related to its poor immu-six days later they received 50 ml anti-BBG2Na or anti-
BB (controls) polyclonal serum i.n., with equivalent ELISA nogenicity in infants (Wagner et al., 1989). Also, while the
immunological role of oligosaccharides remains unclear,titers of 104 vis-a`-vis RSV-A and BB, respectively, and
were sacrificed after 5 days. As shown in Fig. 5B, anti- they have been shown to act as immune decoys or to be
capable of directly blocking virus neutralizing responsesBBG2Na completely eliminated detectable virus from the
lungs of chronically infected SCID mice. In contrast, virus (Alexander and Elder, 1984; Elder et al., 1986; Kniskern
et al., 1994; Skehel et al., 1984; Garcia-Beato et al., 1996).was detected in the lungs of all SCID mice that received
anti-BB polyclonal serum. The capacity of anti-BBG2Na Although glycosylation of the RSV G protein is antigeni-
cally important (Palomo et al., 1991), and glycosylated Gantibodies to prevent and eliminate RSV-A infection in
normal and immunocompromised mouse lungs, respec- proteins are protective in rodent models (Stott et al., 1986;
Olmsted et al., 1989), our data clearly demonstrated thattively, confirms that such antibodies are important and
sufficient for BBG2Na-induced pulmonary protection. Our glycosylation is not necessary to elicit a sterilizing lung
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protective immune response in BALB/c mice or cotton nized in a similar fashion with RSV-A. Comparable short-
term efficacy using other RSV subunit antigens was ob-rats. The data also indicate that prokaryotically ex-
pressed BBG2Na is at least in part antigenically authen- served only when a baculovirus-expressed RSV FG chi-
mera was coadministered i.n. with Sigma cholera toxintic relative to native RSV-A and RSV-B G proteins.
Elements critical for an ideal viral vaccine include the B subunit (Oien et al., 1994). Similar long-term efficacy
for a subunit RSV antigen has not been previously re-inducibility, durability, and heterogeneity of protective im-
mune responses. In relation to lung protection in rodent ported. This novel finding indicates that ip immunization
with either BBG2Na or RSV-A under our experimentalmodels, our data clearly fulfill these criteria. First,
BBG2Na demonstrated a potent capacity to induce lung conditions induces acute and memory immune re-
sponses capable of effector functions at distal nasal mu-protective immune responses against homologous virus
challenge in both mice and cotton rats. This protective cosa. It also confirms that the G2Na fragment contains
immunogenic determinants that are important and suffi-efficacy compared favorably with the pulmonary protec-
tion observed in RSV-A-immunized animals and that pre- cient for upper respiratory tract protection of mice. The
local detection of anti-RSV-A IgG is consistent with aviously described for virion purified (Hancock et al., 1995;
Murphy et al., 1989; Routledge et al., 1988; Walsh et al., putative protective role for such antibodies. Interestingly,
im administration of BBG2Na was less efficacious than1987) or rVV-expressed RSV G or F proteins or fragments
thereof (Elango et al., 1986; Johnson et al., 1987; Olmsted ip in terms of upper respiratory tract protection in the
mouse model, suggesting that the immunization route iset al., 1989; Stott et al., 1986, 1987). Second, ip immuniza-
tion of mice with BBG2Na resulted in long-term protec- important. Nonetheless, the protective efficacy of
BBG2Na observed after im immunization was superiortion of the lower respiratory tract against RSV-A chal-
lenge. These data are consistent with, and extend, those to that of RSV-A under our experimental conditions and
contrasted starkly with the lack of protection induced byof Trudel et al. (1991), in which a G derived peptide
coupled to KLH protected mice over a 24-week period. a comparable dose of an FG chimera (Oien et al., 1994).
In contrast to mice, and consistent with previous reportsThey also compared favorably with a subgroup A live
attenuated RSV strain, which protected mice for at least concerning F and G proteins (Elango et al., 1986; Johnson
et al., 1987; Murphy et al., 1990), im immunization of6 months after i.n. immunization (Palladino et al., 1995).
Finally, when challenged with a representative RSV-B cotton rats with BBG2Na failed to protect their upper
respiratory tracts from virus challenge. Thus, nasal tractstrain, both mice and cotton rats demonstrated lung pro-
tection after immunization with BBG2Na. Thus, the re- protection is also species-dependent. This lack of upper
respiratory tract protection may be due to diminishedsults suggest that BBG2Na may induce protective im-
mune responses against a broad range of RSV strains. immunogenicity of BBG2Na in cotton rats compared with
mice, as suggested by the serology data.As expected, cross-protection was less effective than
homologous protection in terms of viral clearance from The kinetics of virus clearance from the lungs, and to
a lesser extent from the nasal tract, are consistent withlungs. Nonetheless, the extent of this cross-protection is
striking when one considers that RSV G proteins were a rapid dynamic local response to the viral insult, and
thereby, antibody-mediated protection. The serum pas-previously noted for their limited, or for their lack of, heterol-
ogous protective efficacy (Johnson et al., 1987; Stott et al., sive transfer experiments confirmed that anti-BBG2Na
antibodies are mechanistically important and sufficient1987; Sullender et al., 1990). A possible explanation is that
the immunogenicity of the cross-reactive/protective epi- for both lung protection against RSV-A challenge and
virus clearance. Similar results were previously reportedtope(s) is increased due to the lack of oligosaccharides.
Also, the epitope hierarchy of the native G protein may be using polyclonal and MAbs (including G-specific MAbs)
(Hemming et al., 1995 and articles cited therein; Taylorsuch that the cross-reactive/protective epitope(s) is poorly
immunogenic in the context of the whole protein, but as- et al., 1984a). Furthermore, although T cells are impli-
cated in resolving primary RSV pulmonary infection (Can-sumes a more important immunogenicity in the context of
the smaller G2Na fragment. These hypotheses are consis- non et al., 1987; Munoz et al., 1991), our results indicated
that they are not necessary for lower respiratory tracttent with the identification of the C-terminal third of the
native G protein as being antigenically important and con- viral clearance from BBG2Na-immunized mice. Contrary
to lung protection, mouse nasal tracts were never pro-taining epitopes of many RSV strain-specific MAbs, whose
binding appears to be O-linked carbohydrate-dependent tected from RSV-A challenge following passive transfer
of anti-BBG2Na. Thus, while the rapid initial clearance(Garcia et al., 1994; Palomo et al., 1991).
Surprisingly, in view of parenteral administration using of nasal tract virus suggested an antibody role in protec-
tion, this cannot be concluded from our data. These re-Alhydrogel as adjuvant, BBG2Na also demonstrated na-
sal tract protective efficacy against homologous virus sults are consistent with other experiments using RSV-
specific human immune globulin, in which mouse andchallenge. The potent, durable, and rapid nasal tract pro-
tection observed in BALB/c mice after ip administration cotton rat nasal tracts were not protected following pas-
sive transfer (Graham et al., 1995; Prince et al., 1987).compared favorably with that observed in mice immu-
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